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Introduction: Chitotriosidase (CTO) is a human chitinolytic enzyme secreted by activated mac-
rophages and polymorphonuclear neutrophils. Albeit not specific for sarcoidosis, it is increased
in over 90% of patients with active disease. The aims of this study were to correlate CTO mea-
surements with clinical assessment of sarcoidosis and to test CTO as a marker of sarcoidosis
relapse.
Methods: 95 patients were followed-up for 24e60 months. Serial CTO measurements were per-
formed every 3e6 months and correlated to clinical symptoms, lung function (FVC and DLco)
and chest X-ray. In 38 patients clinical outcome status (COS) at 5 years was determined.
Results: Initial CTO levels were significantly higher in patients with impaired FVC/DLco
(p Z 0.011 for both) but there was no correlation with standard chest X-ray stages. Patients
with Loefgren’s syndrome had significantly lower initial and control CTO level compared to
other patients (pZ 0.011 and pZ 0.001, respectively). At follow-up there was a positive cor-
relation of CTO and deterioration of clinical symptoms (p < 0.001), chest X-ray (p < 0.001) and
FVC/DLco (pZ 0.012 and pZ 0.086, respectively). Control CTO levels were significantly lower
in no disease groups versus minimal or persistent disease group as defined by COS (p Z 0.003
and p < 0.001, respectively). At relapse CTO increased for 100% or more from baseline value in
12/14 patients.522 28 26; fax: þ386 1 522 23 47.
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776 M. Harlander et al.Conclusions: It was shown that CTO correlates with certain sarcoidosis phenotypes (Loefgren’s
syndrome, COS) and that serial measurements of CTO correlate with clinical symptoms, chest
radiographs and lung function.
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Chitotriosidase (CTO) is a human chitinolytic enzyme
secreted by activated macrophages and polymorphonuclear
neutrophils. Although the role of CTO in human is still not
completely elucidated, it is most likely a part of the innate
immune system against chitin containing pathogens, such
as fungi and some parasites [1,2]. Its expression is upre-
gulated by INF-g, TNF-a, LPS and GM-CSF and down-
regulated by IL-10 [3,4]. In population there is a common
polymorphism in the CTO gene (CHIT1) e a 24-base pair
duplication which results in the production in an inactive
enzyme. The approximate frequency of normal subjects
(wt/wt) is 60%, heterozygotes (wt/H) 34% and homozygotes
(H/H) 6% [2,5,6]. Heterozygotes were reported to have
about 50% of CTO activity compared to wild type, whereas
homozygotes have no CTO activity in any body tissue [2].
While increased CTO is not specific for sarcoidosis [2], it
was shown to be very sensitive biomarker of active
sarcoidosis [7e11]. Sensitivity is estimated to about 90%
which exceeds the sensitivity of commonly used biomarker
angiotensin convertase enzyme (ACE) of about 60% [12].
CTO in serum and bronchioalveolar lavage (BAL) correlated
with radiological stages of sarcoidosis [7,9,10]. CTO in BAL
was shown to correlate with quantitative HRCT score of
lung volume affected by sarcoidosis [13]. There is some
evidence that CTO could have prognostic value in sarcoid-
osis [10]. CTO was proposed as a follow-up marker both for
detecting relapses of the disease and for determining the
adequate patient management [10]. It was previously
shown that treatment with corticosteroids reduces the ac-
tivity of CTO [8,9]. Similarly to ACE, CTO most likely re-
flects granulomatous burden of the disease [9,14,15] and
this reduces after corticosteroid treatment is initiated in
majority of patients [16,17]. On the other hand, cortico-
steroid resistant sarcoidosis has been described. It is
characterized by increased TNF-a release of alveolar mac-
rophages [18]. TNF-a antibodies can be efficient in such
cases [19e21]. There is currently no data on how CTO
changes with various treatments in corticosteroid resistant
sarcoidosis.
The aims of this study were to correlate CTO measure-
ments with clinical assessment of sarcoidosis and to test
CTO as a marker of sarcoidosis relapse.Methods and subjects
Subjects
The study comprised 100 consecutive patients with newly
diagnosed sarcoidosis according to ATS/ERS/WASOG criteria
[22] at the Department of pulmonary diseases of University
medical centre Ljubljana, Slovenia. Patients wereprospectively included from June 2006 to May 2011 imme-
diately after first diagnostic work-up before introduction of
any treatment. In five subjects there was no CTO activity in
any sample and they were excluded from further analysis
(presumed to be homozygotes for CHIT1 duplication poly-
morphism). The data from 95 patients is reported in the
results.
All subjects gave a written consent to participate in the
study which was approved by the National Ethics Commit-
tee of the Republic of Slovenia (numbers 198/05/04 and
203/02/11). The patients included were corticosteroid
naı¨ve at the time of the first sampling.
Follow-up
Study subjects had regular follow-up at our clinic every 3e6
months or more often if necessary due to symptoms. There
were followed-up from 24 to 60 months (median 38.5
months). Regular examinations included: clinical assess-
ment, chest X-ray, lung function testing and CTO sampling.
CTO measurements were not available to the clinician at
the time of clinical examination to avoid biasing.
Blood sampling and measurement of CTO activity
Venous blood was drawn on each occasion into a tube
without anticoagulant, centrifugated and immediately
stored at 20 C. The CTO activity was determined in
serum using the 22 mM 4-methylumbelliferyl-b-D-N,N0,N00-
triacetylchitotriosiose (4 MU-chitotrioside, Sigma Chemical
Co.) in citrate phosphate buffer (pH 5.2) as an enzymatical
substrate. Five microlitres of serum or BAL was incubated
with 100 mL of substrate for 1 h at 37 C. The reaction
was stopped by adding 2.5 mL of 0.3 M glycine/NaOH
buffer (pH 10.6). The reaction product, fluorescent 4-
methylumbelliferone, was measured using a PerkineElmer
fluorimeter at excitation wave length 365 nm and emission
465 nm. The CTO activity was expressed in nmol/h/mL.
Clinical symptoms assessment
At presentation symptoms such as fever, fatigue, joint pain,
cough, dyspnea or chest pain were documented. At follow-
up visits the symptoms were graded as new, persisting or
none. The patients presenting with acute clinical picture
consisting of bihilar lymphadenopathy, erythema nodosum
and arthalgia were considered to have Loefgren’s syn-
drome. Screening for extrapulmonary sarcoidosis was done
in all patients. The patients were not systematically eval-
uated for pulmonary hypertension. In cases of persistent
dyspnea and persistent low diffusion for carbon monoxide
echocardiography was done but there were no cases of
pulmonary hypertension.
Table 1 Patient’s characteristics, initial clinical evalua-
tion and CTO activity.
N % CTO
(nmol/h/mL)
p
Gender NS
female 52 54.7 576 (723)
male 43 45.3 795 (726)
Age in yearsa
median
(range)
44 (22e76)
Body mass index
median
(range)
28 (18e44)
Smoking 0.030b
never 70 73.7 672 (642)
former 17 17.9 1104 (858)
current 8 8.4 774 (813)
Clinical presentation 0.011
Lo¨fgren’s
syndrome
13 13.7 468 (168)
Other
patients
82 86.3 870 (754)
Extrapulmonary NS
yes 27 28.4 684 (531)
no 68 71.6 714 (789)
FVC 0.011
80% 79 83.2 636 (660)
<80% 16 16.8 1197 (933)
DLco 0.011
80% 67 70.5 552 (627)
<80% 28 29.5 1094 (897)
Chest X-ray NS
Stage 0 4 4.2 927 (1044)
Stage 1 45 47.4 636 (660)
Stage 2 39 41.1 866 (693)
Stage 3 6 6.3 656 (672)
Stage 4 1 1.1 1218 (e)
Therapy NS
None 23 24.2 696 (707)
Antimycotics 13 13.7 546 (480)
Glucocorticoids 24 25.3 900 (630)
Combination 35 36.8 765 (777)
Data are given as median (IQR). NS (Non significant).
a There is a positive correlation between age and CTO (RhoZ
0.234, p Z 0.028).
b Comparison between never smokers and former smokers.
Serial chitotriosidase measurements in sarcoidosis 777A patient was diagnosed with relapse of sarcoidosis when
after a period of remission there were new symptoms
compatible with sarcoidosis but not accountable to other
causes, a decline in lung function (fall of 12% in FVC or 10%
in DLco), worsening of chest radiograph or new extrap-
ulmonary lesions.
Chest radiographs
Initial chest X-rays were evaluated by two chest radiologists
who were unaware of the clinical diagnosis. In case of
discrepancy in the evaluation, the reported result was
reached by consensus. The chest X-ray readings were
classified into pulmonary sarcoidosis stages: stage
0 (normal chest radiograph), stage I (bilateral hilar lymph-
adenopathy), stage II (bilateral hilar lymphadenopathy
accompanied by parenchymal infiltration), stage III
(parenchymal infiltration without hilar lymphadenopathy)
and stage IV (advanced fibrosis with evidence of honey-
combing, hilar retraction).
Follow-up chest radiographs were classified according to
changes from initial or previous radiograph. Evaluation was
done by side by side comparison of two consequent films.
Radiograph was considered as improved when there was
less parenchymal changes and/or decline in lymph nodes
size or complete normalization of changes, unchanged
when changes persisted without regression and worsened
when there were more parenchymal changes and/or in-
crease in lymph nodes size. Such classification was chosen
to describe changes in lung parenchyma and lymph nodes.
The extent of changes was not graded.
Lung function
Forced vital capacity (FVC) and diffusion capacity for car-
bon monoxide (DLco) were measured using standard tech-
nique. DLco was measured using the single-breath method.
FVC and DLco were classified as normal (80%) or as
impaired (<80%).
At follow-up a change of 12% of FVC and a change of
DLco of 10% were considered significant.
Therapy
Study subjects received therapy for sarcoidosis in case of
persisting symptoms, deterioration of radiographs or lung
function, or extrapulmonary involvement of vital organs.
Subjects received antifungal medication (itraconazole),
corticosteroids (methylprednisolone) or combination of
both, using criteria as described in previous study [23]. In
brief, after a period of observation (3e6 months) the pa-
tients who were considered to have indication for treat-
ment were given one of the described treatment options.
The choice of treatment was made by informed consent e
some patients preferred established therapy with cortico-
steroids while others agreed with experimental therapy
with itraconazole or combination of both agents. The pa-
tients received therapy for 11e16 months. This study was
not randomized. All patients with extrapulmonary involve-
ment of vital organs and patients who did not respond to
antifungal medication received corticosteroids.Clinical outcome status
The patients were classified into subgroups according to
classification proposed by WASOG task force [24]. The
recommended period of observation for determining the
clinical outcome status (COS) is 5 years. The major groups
were no disease, minimal disease (less than 25% of maximal
disease) and persistent disease. The patients were further
divided according to the need for systemic therapy. The
patients currently on therapy (or that received therapy in
the last year) were additionally divided into asymptomatic,
symptomatic and with functional deterioration in the last
778 M. Harlander et al.year. The groups were: COS 1 e no disease, never treated;
COS 2 e no disease, not treated in last year; COS 3 e
minimal disease, never treated; COS 4 e minimal disease,
not treated in last year; COS 5 e persistent disease, never
treated; COS 6 e persistent disease, not treated in last
year; COS 7 e persistent disease, treated in the last year,
asymptomatic; COS 8 persistent disease, treated in the last
year, symptomatic, COS 9 persistent disease, treated in last
year, with functional deterioration.Statistics
For calculations the statistical program SPSS 15.0 was used.
A comparison between groups was done using a non-
parametrical ManneWhitney U-test and for more than 2
groups with KruskaleWallis H test. If KruskaleWallis H test
yielded positive or near positive results individual groups
were tested pair-by-pair with ManneWhitney U test. Two
related variables were compared using Wilcoxon signed-
rank test. Correlations were calculated using Spearman’s
rank correlation. A p value under 0.05 was considered as
significant. As the data has asymmetrical distribution and
non-parametrical test were used, median values and
interquartile ranges (IQR) are reported throughout the
article.Figure 1 A e Initial and control CTO values (3e6 months
after therapy discontinuation or observational period of 12e15
months) in patients with Loefgren’s syndrome compared to
other patients. *Significant difference between group with
Loefgren’s syndrome and other patients in initial CTO
(pZ 0.011). #Significant difference between groups in control
CTO (p Z 0.001). B e Initial and control CTO values in COS
groups. *No significant difference in initial CTO between groups
with no disease and minimal disease (p Z 0.106) or between
groups with no disease and persistent disease (p Z 0.074).
#Significant difference in control CTO between groups with no
disease and minimal disease (p Z 0.003) and between groups
with no disease and persistent disease (p < 0.001).Results
Initial evaluation of sarcoidosis
The detailed results are shown in Table 1. There was no
correlation between CTO and gender or CTO and body mass
index (BMI). There was a positive but weak correlation
between age and CTO. Former smokers had significantly
higher CTO compared to never smokers while the differ-
ence did not reach statistical significance against current
smokers. Patients presenting with Loefgren’s syndrome had
significantly lower levels of CTO compared to other patients
(Fig. 1A). Extrapulmonary locations were: uvea (n Z 9),
extrathoracic lymph nodes (n Z 6), skin (n Z 4), liver
(n Z 3), nervous system (n Z 3), bone marrow (n Z 2),
bladder (n Z 1) and kidneys (n Z 1). Two patients had
more than one organ affected (uvea þ extrathoracic lymph
nodes and uvea þ liver). There was no significant difference
in CTO levels between patients with or without extrap-
ulmonary sarcoidosis. Patients with impaired FVC or DLco
had significantly higher CTO levels compared to patients
with normal FVC or DLco. In this group of study subjects
there was no correlation between chest X-ray staging of
pulmonary sarcoidosis and CTO levels.Follow-up and serial CTO measurements
There was a significant decline in control CTO values (3e6
months after therapy discontinuation or after 12e15
months of observation for patients without therapy) both in
patients with Loefgren’s syndrome (median CTO 126 nmol/
mL/h, IQR 253 nmol/mL/h, pZ 0.01) and in other patients
(median CTO 351 nmol/mL/h, IQR 338 nmol/mL/h,p < 0.001). The control CTO values were significantly lower
in patients with Loefgren’s syndrome (p Z 0.001).
The data (Table 2) showed very good correlation of CTO
and changes in clinical symptoms and chest X-ray. CTO was
particularly increased when new clinical symptoms or pro-
gression of chest X-ray changes were noted. Significantly
higher CTO levels were measured when there was decline in
FVC compared to increase or stable values of FVC but this
was only borderline significant for DLco. There was no dif-
ference between CTO in stable lung function or at increase.
Table 2 Follow-up and CTO activity.
CTO
(nmol/h/mL)
p
Clinical symptoms <0.001
New 948 (447)
Persisting 451 (403)
None 287 (251)
FVC 0.012a
Decline 602 (576)
Stable 336 (275)
Increase 373 (310)
DLco 0.086a
Decline 527 (696)
Stable 315 (362)
Increase 327 (203)
Chest X-ray <0.001
Improved 326 (233)
Unchanged 494 (397)
Worsened 876 (628)
Data are given as median (IQR).
a Comparison between decline and stable FVC or DLco.
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In total, COS at 5 years could be determined for 38 (40%)
patients. Eleven patients that could complete 5 years were
lost to follow-up (22.4% of potential 5-year follow-up
group). Due to small number of patients the analysis was
done only on major COS groups: no disease (COS 1 and 2),
minimal disease (COS 3 and 4) and persistent disease (COS
5e9). The results are shown in Table 3 and Fig. 1B. The
initial CTO values did not correlate with COS but there was
a trend towards higher CTO values in patients with minimal
or persistent disease (p Z 0.106 for no disease versus
minimal disease and p Z 0.074 for no disease versus
persistent disease). The control CTO values were signifi-
cantly lower in the patients with no disease compared to
patients with minimal (p Z 0.003) or persistent disease
(p < 0.001). The difference was significant even if patientsTable 3 COS at 5 years for 38 patients compared to initial an
observational period of 12e15 months).
COS N at year 5 % CTO
No disease 1 7 18.4 480
2 8 21.1 468
Minimal disease 3 3 7.9 513
4 4 10.5 1184
Persistent disease 5 0 0 e
6 3 7.9 1470
7 8 8.4 1218
8 2 5.3 399
9 3 7.9 525
Data are given as median (IQR).
*No significant difference in initial CTO between groups with no dise
disease and persistent disease (p Z 0.074).
**Significant difference in initial CTO between groups with no diseas
disease and persistent disease (p < 0.001).with Loefgren’s syndrome were excluded from the analysis
(5 completed the required follow-up, 1 had persistent
disease).
Relapse of sarcoidosis
Subjects who had relapse of sarcoidosis in the observational
period (median time from diagnosis to relapse was 28
months) had significantly higher CTO at presentation
compared to subjects who did not have relapse (Table 4).
CTO at diagnosis was however neither sensitive nor specific
for predicting future relapses, as receiver operating char-
acteristic (ROC curve) yields area under the curve of only
0.680. The difference disappeared 3e6 months after ther-
apy was discontinued (or after 12e15 months of observa-
tion for patients who did not receive any therapy). At the
time of relapse there was a distinct peaking of CTO (Fig. 2).
In 12 of 16 patients with relapse the increase of CTO was
over 100% of control value (range 108e532%), in 1 patient
the increase was 48% and in 1 patient 5%. In no patient CTO
at relapse was below the control value. In 2 patients we
could not obtain control CTO values due to early relapse
after termination of therapy.
Discussion
In this study CTO was shown to correlate with the clinical
presentation of sarcoidosis, lung function (FVC and DLco)
and age of patients. There was lack of correlation with
chest X-ray staging of pulmonary sarcoidosis. A drawback of
this study is that it included mostly patients with sarcoid-
osis stages I and II (88.5%) and only small number of patients
with other stages. A correlation of all radiographical stages
and serum CTO levels was previously reported [7], but
further studies only partially confirmed this. In two studies
CTO was higher in stages III and IV as compared to 0 and I
[10,25] and in one there was borderline positive correlation
between stage I and stages IIeIV [9]. This is likely due to
other factors that affect CTO level, such as the extent of
lung infiltration or large extrapulmonary granulomatousd control CTO (3e6 months after therapy discontinuation or
(nmol/mL/h) Control CTO (nmol/mL/h)
(741) 468 (609)* 192 (195) 179 (212)**
(199) 49 (194)
(498) 903 (825) 588 (1377) 483 (315)
(627) 378 (306)
714 (972) 456 (684)
(1146) 1032 (420)
(972) 456 (168)
(588) 264 (e)
(315) 174 (138)
ase and minimal disease (p Z 0.106) or between groups with no
e and minimal disease (p Z 0.003) and between groups with no
Table 4 CTO values in patients with and without relapse.
Control CTO were obtained 3e6 months after therapy
discontinuation or after observational period of 12e15
months.
Relapse p
Yes No
Subjects 16 (16.8%) 79 (83.2%)
CTO (nmol/h/mL) 0.029
NSInitial 1032 (699) 584 (699)
Control 293 (309) 320 (357)
At relapse 990 (649)a e
Data are given as median (IQR).
a Significant difference between control CTO and CTO at
relapse (p Z 0.001).
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Figure 2 Representative charts of a patient with sponta-
neous remission (A) and patient with remitting/relapsing
course of sarcoidosis (B). On the second chart dashed vertical
line indicates initiation of the therapy and dotted vertical line
termination of the therapy.
780 M. Harlander et al.infiltration. Moreover, chest X-ray stages do not reflect
activity of the disease but merely describe the presence of
lymphadenopathy and lung infiltration at one time point
[26]. To obtain information about activity of inflammation
serial radiographs are necessary which was done in the
follow-up part of this study. On the other hand, it was
observed that patients with FVC or DLco below normal
values had significantly higher CTO values. Higher CTO
values most likely reflect higher granulomatous infiltration
which is the cause of decline in lung function. Serum sol-
uble interleukin-2 receptor (sIL-2R) is also considered a
biomarker of active sarcoidosis and it was reported to
positively correlate with CTO [8,25]. It is considered a
marker of CD4þ lymphocyte activation [27] (as opposed to
CTO which derives from macrophages). Contrary to CTO,
sIL-2R was higher in lower radiographic stages of sarcoidosis
[25,27] and did not correlate with impaired lung function
[27]. High sIL-2R is possibly a predictor of good clinical
outcome of sarcoidosis [27] although increased sIL-2R
values were observed in progressive sarcoidosis also [25].
This suggests that CTO and sIL-2R might be used as com-
plementary biomarkers (in example, low sIL-2R and high
CTO could indicate complicated disease and vice versa) but
further research is needed to explore this hypothesis.
The patients with Loefgren’s syndrome had significantly
lower CTO compared to other patients. This group is known
to have the best outcome, experiencing spontaneous
remission in over 80% [22] and this is in line with hypothesis
that low CTO indicates good clinical outcome [10]. Inter-
estingly, in a study on sIL-2R in sarcoidosis, patients with
pulmonary sarcoidosis and erythema nodosum (6/8 patients
had classic Loefgren’s syndrome) had higher sIL-2R values
compared to patients with pulmonary sarcoidosis only [27].
Bargagli et al. reported correlation between CTO and
clinical outcome status (COS) [10]. In particular, patients
with persistent disease (COS 5, COS 6, COS 8 and COS 9) had
higher CTO values compared to COS 1 group. The results
from this study shows similar pattern, CTO being lower in no
disease group as compared to minimal or persistent disease
groups. Although the difference in initial CTO values did not
reach statistical significance the authors believe there is a
true association that would be reach statistical significance
in larger number of patients. Control CTO values were
significantly lower in no disease group compared to othertwo groups. This shows that persistently high CTO values
after therapy or observational period might be even more
predictive for chronic disease.
Positive correlation between age and CTO has been
previously described in healthy subjects [28,29] so this
finding in this study group could reflect normal aging pro-
cess. On the other hand, it has been reported that older
patients with sarcoidosis have worse prognosis and worse
clinical outcome status score [24].
The observation that CTO was significantly higher in
former smokers compared to never smokers was unex-
pected. It has been reported that smoking increases CTO
activity in chronic obstructive pulmonary disease [30,31]
but this does not explain the observation. While it could
be just a chance occurrence, it was reported that smoking
cessation increases metabolic activity of macrophages [32].
The influence on airway inflammation differs in patients
with chronic obstructive disease compared to asymptom-
atic smokers [33]. In one study of wound healing smoking
cessation restored inflammatory but not proliferative pro-
cesses [34]. If this somehow applies to sarcoid macrophages
remains to be elucidated.
The limitation of the reported data is that CTO values
are not corrected for genotype (common inactivating 24 bp
duplication polymorphism of CHIT1 gene). In one study it
Serial chitotriosidase measurements in sarcoidosis 781was shown that the distribution of CHIT1 duplication poly-
morphism in Slovenian sarcoidosis patients does not differ
from general population [5]. Currently there is no infor-
mation on whether CHIT1 polymorphism has any effect on
sarcoidosis phenotype as no previous studies on sarcoidosis
and CTO reported genetic data. Our limited unpublished
data suggests that there are no differences in sarcoidosis
phenotypes between wt/wt and wt/H subjects (and no
clustering), but further research is needed to confirm this.
In the follow up part of the study serial measurements of
CTO showed a good correlation with changes in chest X-ray
and clinical symptoms and less strong correlation with
changes in lung function. A drawback of this data is that
changes in chest X-ray were not quantified using a scoring
system. Nevertheless, side by side evaluation of chest X-ray
is considered a valid and accurate method [35,36]. The
results in this study might be biased to some extent because
time sequence of chest X-rays was known. In previous
longitudinal studies similar relationships were found for
ACE [37,38]. The major advantage of CTO in comparison to
ACE is its greater sensitivity [7e10]. The limited data on sIL-
2R suggests association between decline of sIL-2R and
improvement in chest X-ray [27]. CTO could thus be used to
reduce the number of needed investigations for monitoring
disease progression as this was unlikely if there was no in-
crease in CTO value. In future studies it would be of in-
terest to compare CTO activity and 18F-FDG PET/CT which
is very sensitive imaging method for detection of the
extension of inflammation in granulomatous sites and can
assess activity of inflammation [39e41].
Finally, CTO was also evaluated as a marker of relapse of
the disease. The major shortcoming of this data is that
patients were observed for uneven periods of time (24e60
months). Nevertheless, high initial CTO value appeared to
be weak predictor of future relapse. At relapse an increase
from control values of over 100% was detected in 12/14
patients.
In conclusion, CTO was shown to correlate with certain
sarcoidosis phenotypes, such as Loefgren’s syndrome and
COS. Additionally, it was shown that serial measurements of
CTO positively correlate with clinical symptoms, chest ra-
diographs and lung function. This confirms previous obser-
vations that CTO is a good marker of sarcoidosis activity.
Taking high sensitivity of CTO for sarcoidosis in to account,
serial CTO measurements could be used to reduce the
number of other diagnostics procedures (such as chest ra-
diographs) or to support decision for additional examina-
tions (such as PET-CT).
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